US FDA Guidance On Artificial Intelligence For Regulatory Decision-Making Expected This Year

 
• By M. Nielsen Hobbs
  
Generate a summary of this article
Listen to this article
Beta

Draft guidance will offer a risk-based framework for accessing the credibility of AI and help ensure that AI models used to answer regulatory questions are sufficiently credible for a particular ‘context of use,’ CDER’s Tala Fakhouri says.

Coming Soon
Artificial intelligence guidance will arrive this year • Source: Shutterstock

The US Food and Drug Administration is planning to issue a draft guidance on the use of artificial intelligence in regulatory decision making by the end of the year. The move would be the most concrete oversight action to date by the agency, which has been ramping up its AI activities with discussion papers, workshops and collaborations.

Key Takeaways

  • Draft guidance from FDA will take a risk-based approach to assessing AI use in regulatory decision making.

“I can’t give you the details. As much as I would love to I can’t,” Tala Fakhouri, associate director for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from AI

Artificial Intelligence: CDER’s New Council Takes Charge Of Oversight, Coordination

 
• By Sue Sutter

The Artificial Intelligence Council takes over the work that three different entities in the US FDA’s drugs center had been performing. The new, centralized entity will develop and promote consistency of AI-related activities and advance innovative uses.

Use AI In Health Technology Assessments Only When Valuable, England’s NICE Tells Pharma Firms

 
• By Eliza Slawther

Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.

$14m Handout Anyone? Shanghai Offers Raft Of New Biopharma Incentives

 
• By Brian Yang

Shanghai issues a new set of policies and financial incentives designed to support and speed up regulatory and commercial activities in the biopharma sector, in a comprehensive stimulus package for companies based in the major Chinese city.

Parexel Execs On Regulatory Harmonization, AI Impact, RWE Challenges

 
• By Vibha Ravi

From the US FDA’s ISTAND Program to EU’s Melloddy Initiative, and from the global challenges of real-world data to the opportunities in India, Parexel’s EVP for Clinical Data and Digital Services, chief strategy officer and India head speak on a range of topics in this interview with the Pink Sheet.

More from Advanced Technologies

CAR-T Therapies: Rethinking Of Postmarketing Requirements And REMS Urged

 
• By Sue Sutter

Long-term follow-up requirements have taken a conservative approach but could be ripe for re-examination and global harmonization given the years of experience with the products, Kite Pharma executive director says; former FDA gene/cell therapy office head Wilson Bryan calls for elimination of the classwide REMS.

test

 
• By Sabbah and Saba Afreen

test

Gene Therapies: CoGenT Pilot Could Help With Regulatory Convergence Earlier In Development TEST

 
• By Sue Sutter

Program for collaborative reviews of gene therapy applications is getting under way with the European Medicines Agency. After launch, the pilot could be expanded to earlier discussions around CMC and pharm/tox data requirements, FDA’s Nicole Verdun said.